CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours
2002

CHEK2 Variants and Breast Cancer Risk

Sample size: 68 publication Evidence: moderate

Author Information

Author(s): Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams R D, Bevan S, Bishop K, McGuire S, Houlston R S, Eeles R A

Primary Institution: Royal Marsden NHS Trust

Hypothesis

Do other CHEK2 variants confer an increased risk of breast cancer?

Conclusion

The study found that certain CHEK2 variants are associated with an increased risk of breast cancer, suggesting that tumorigenesis may not involve loss of the wild type allele.

Supporting Evidence

  • Three of the 68 breast cancer patients carried the 1100delC variant, which is associated with increased breast cancer risk.
  • None of the missense variants were found in 300 healthy controls, suggesting they may contribute to breast cancer risk.
  • The study implies that CHEK2 mutations may account for around 7% of familial breast cancer cases.

Takeaway

Some changes in a gene called CHEK2 can make people more likely to get breast cancer, and these changes don't always mean the normal version of the gene is lost.

Methodology

The study screened 68 familial breast cancer cases for CHEK2 mutations and analyzed tumor DNA for allelic imbalance.

Limitations

Germline DNA was not available from other family members to confirm the presence of variants.

Participant Demographics

All participants had a strong family history of breast cancer, with a median age at diagnosis of 47 years.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI: 1–12%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600637

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication